2O9 Stock Chart & Stats
€0.10
>-€0.01(-4.41%)
At close: 4:00 PM EST
€0.10
>-€0.01(-4.41%)
Day’s Range― - ―
52-Week Range€0.01 - €0.13
Previous CloseN/A
Volume0.00
Average Volume (3M)17.00
Market Cap
€13.81M
Enterprise Value€26.40M
Total Cash (Recent Filing)€6.20M
Total Debt (Recent Filing)€5.80M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding437,018,680
10 Day Avg. Volume52
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.38
Price to Sales (P/S)3.23
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€1.33M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Margin ExpansionRevenue up ~26% with gross margin rising to ~40% represents durable commercial traction and improving unit economics. Higher per-test margins improve scalability as volumes grow, making future profitability more achievable if adoption and reimbursement continue to expand.
Proprietary Biomarker + AI Diagnostic OfferingA focused diagnostic product (KidneyIntelX) that fuses biomarkers and AI creates a structural competitive edge: clinical integration, data-driven algorithm refinement, and sticky workflow placement in care pathways that can sustain recurring test volumes and barriers to entry.
Improving Cash Burn TrendMaterial reduction in annual cash burn from ~-30.1m to -17.9m indicates management progress on cost control and operational leverage. A sustained downward trajectory in cash outflows reduces near-term financing pressure and enhances runway for commercialization efforts.
Bears Say
Negative Shareholders' EquityNegative equity signals a stressed capital structure that limits financial flexibility and borrowing capacity. It usually necessitates recurring external financings or equity raises, increasing dilution risk and constraining the company’s ability to invest in scaling operations over the medium term.
Persistent Negative Free Cash FlowSustained negative FCF implies continual dependence on external capital to fund operations. This recurring financing need can compress long-term returns, raise cost of capital, and force strategic trade-offs between growth investments and survival if revenue scale does not accelerate.
Very Small Revenue Base Vs Large LossesA tiny revenue base (~3m) coupled with extremely wide net losses indicates fixed cost structure far exceeds current scale. Until test volumes and reimbursements rise meaningfully, profitability remains distant, raising execution risk around commercial adoption and sustainable margins.
Renalytix News
2O9 FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest stock price was €0.01 and its highest was €0.13 in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is €13.81M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Nov 03, 2026 which is in 102 days.
How were Renalytix’s earnings last quarter?
Renalytix released its earnings results on Mar 26, 2026. The company reported -€0.019 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.019.
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Overvalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 437,018,680 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Renalytix reported an EPS of -€0.019 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.636%.
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in DE:2O9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Renalytix
Renalytix Plc specializes in developing cutting-edge in vitro diagnostic solutions for kidney diseases, leveraging the power of artificial intelligence. Their primary offering, KidneyIntelX, is an advanced diagnostic platform. It employs a sophisticated AI-enabled algorithm that synthesizes various data streams, such as scientifically validated blood biomarkers, inherited genetic factors, and personalized patient data extracted from electronic health record systems. The output is a unique, individualized risk score for each patient. These innovative tools serve multiple critical functions: they assist in the diagnosis and prognosis of kidney ailments, optimize clinical patient management, facilitate patient stratification for pharmaceutical clinical trials, and aid in the discovery of novel drug targets. The company has secured several pivotal license agreements. A partnership with Mount Sinai Health System grants rights for the development and commercialization of AI applications in kidney disease diagnostics. Another agreement with Joslin Diabetes Center, Inc. focuses on creating and marketing biomarker-based products for the diagnosis and prediction of kidney conditions. Furthermore, Renalytix holds a license with Kantaro Biosciences LLC for laboratory assays designed to detect SARS-CoV-2 antibodies. In a collaborative effort, Renalytix has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine. This alliance aims to implement an advanced clinical care paradigm, specifically designed to enhance kidney health and mitigate the progression of kidney disease and subsequent renal failure in high-risk patient populations. Founded in 2018, the company operated under the name Renalytix AI plc until its change to Renalytix Plc in June 2021. Its corporate headquarters are situated in New York, New York.
Technical Analysis
EKF Diagnostics Holdings
―
Genedrive
―
Oxford BioDynamics
―
Proteome Sciences
―
Verici Dx Plc
―